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Introduction
Our knowledge of the structural substrates, spatial composition, and functional significance of endocannabinoid (eCB) signaling has recently undergone rapid expansion because of the continued identification of novel eCBs and related lipid mediators, bioactive intermediates, metabolic enzymes, cannabinoid receptors, and contextdependent recruitment of signaling pathways downstream from cannabinoid receptors (Brown, 2007; Daigle et al., 2008; Egertova et al., 2007; Lauckner et al., 2008; Mackie et al., 2006; Wei et al., 2006) . In the adult CNS, eCBmediated retrograde synaptic signaling implies the selective recruitment of CB1 cannabinoid receptors (CB1Rs) to both inhibitory and excitatory presynaptic terminals thus allowing sensing of on-demand eCB release from postsynaptic neurons (Lutz, 2004) . The activity-dependent release of eCBs thereby controls synaptic plasticity in many brain regions including the neocortex, hippocampus, cerebellum, and basal ganglia (Kreitzer et al., 2001; Matyas et al., 2008; Ohno-Shosaku et al., 2002; Wilson et al., 2001b; Wilson et al., 2001a) . Although the molecular machinery underscoring retrograde eCB release in the postnatal brain is well-established (Piomelli, 2003) , our understanding of eCB functions during neurodevelopment has just begun to unfold. Contemporary evidence indicates that in the developing central nervous system (CNS) anandamide (AEA) and 2-arachidonoylglycerol (2-AG), the main known eCBs, and  9 -tetrahydrocannabinol ( 9 -THC), the major psychoactive component in cannabis (Cannabis spp.) , target cannabinoid receptors differentially on neural progenitors Molina-Holgado et al., 2007) , immature neurons (Berghuis et al., 2005; Berghuis et al., 2007; Mulder et al., 2008; Watson et al., 2008) , and glia Molina-Holgado et al., 2002) (Fig. 1) . Functional studies have demonstrated that this family of lipid mediators is involved in the regulation of neural progenitor proliferation and lineage commitment (Galve-Roperh et al., 2006; Mulder et al., 2008) ; instructs the migration and differentiation of neuronal precursors (Berghuis et al., 2005; Berghuis et al., 2007; Harkany et al., 2007; Mulder et al., 2008) ; and affects the onset of synaptic communication in neonatal A c c e p t e d M a n u s c r i p t Tibor Harkany et al. Endocannabinoids in the developing brain Date of submission : February 19, 2008 3 neuronal networks Bernard et al., 2005; Mereu et al., 2003) . While the concepts described herein are primarily derived from experimental data on mammalian expression systems (see also: (Watson et al., 2008) ) with well-accepted ligands, metabolic enzymes, and CB1Rs in neurons, the recent expansion of metabolic pathways critical for eCB synthesis and degradation Liu et al., 2006; Mulder et al., 2006; Simon et al., 2006; Wei et al., 2006) , and the identification of novel cannabinoid receptors, particularly the orphan G protein-coupled receptor GPR55 (Baker et al., 2006; Johns et al., 2007; Lauckner et al., 2008; Oka et al., 2007; Ryberg et al., 2007) suggest a future leap in our understanding of eCB functions during brain development.
Developmental specification of endocannabinoid signaling
The molecular organization of eCB metabolism and respective receptor systems during brain development is such that eCBs may effectively tune the cellular specification programs of both neural progenitors and lineagecommitted neuronal precursors . At present, a comprehensive neuroanatomical analysis of eCB signaling components during brain development is lacking; which is primarily due to our restricted knowledge of key enzymes regulating eCB bioavailability, and of eCB-sensing receptors. The parallel, and often compensatory metabolic pathways controlling eCB levels, and the promiscuity of eCB actions on a broad range of developmentally-regulated receptors and ion channels (Matias et al., 2006; Piomelli, 2003; van der Stelt et al., 2005) suggest divergent roles of eCB signaling in the developing brain.
Endocannabinoid (AEA, 2-AG) concentrations vary substantially throughout brain development (Berrendero et al., 1999; Fernandez-Ruiz et al., 2000) : low AEA levels are present in the brain at mid-gestation with gradually increasing AEA concentrations (3 -6 pmol/g tissue) throughout the perinatal period until adult concentrations are reached (Berrendero et al., 1999) . In contrast, prenatal 2-AG concentrations (2 -8 nmol/g tissue) are similar to those in young and adult rodent brains (Berrendero et al., 1999; Fernandez-Ruiz et al., 2000) . Although the above data are conclusive on total levels of eCBs in nervous tissues at distinct stages of neurodevelopment, functional implication(s) of these findings are rather ambiguous. This is primarily due to the diverse metabolic roles eCB ligands fulfill, their probable direct interactions tuning neuronal responsiveness (Maccarrone et al., 2008) , their receptor promiscuity, and variations in their effective concentrations at diverse cannabinoid-sensing receptors relevant to initiating downstream signaling in vivo.
Establishment of temporally and spatially-coordinated eCB release requires fine-tuned expression of metabolic enzymes. Two isoforms (α and β) of sn-1-diacylglycerol lipase (DAGL α/β) are the prime 2-AG synthetic enzymes, and are generally accepted to generate physiologically relevant concentrations of 2-AG both in heterologous expression systems and in vivo (Bisogno et al., 2003) . These initial studies suggest a spatial association between the sites of DAGL α/β and CB1R expression in the developing brain at mid-gestation, with dominant subcellular localization in axons populating long-range subcortical and cerebellar projection tracts (Bisogno et al., 2003) . DAGL localization to elongating corticothalamic and intercallosal axons negatively correlates with morphological axon differentiation (Mulder et al., 2008) , and leads to a striking activity-dependent developmental switch, with dendrites of postnatal neurons being preferential sites of eCB synthesis and release A c c e p t e d M a n u s c r i p t Tibor Harkany et al. Endocannabinoids in the developing brain Date of submission : February 19, 2008 4 in mature neurons (Bisogno et al., 2003; Katona et al., 2006; Uchigashima et al., 2007) . A series of candidate enzymes with considerable AEA biosynthetic activity has recently been identified, including N-acylphosphatidylethanolamine-selective phospholipase D (NAPE-PLD) Morishita et al., 2005; Okamoto et al., 2007; Ueda et al., 2005) , /β-hydrolase 4, a lyso-NAPE lipase to form N-acyl ethanolamines (Simon et al., 2006) , and PTPN22, a phosphatase cleaving NAPE-derived phospho-AEA to yield AEA (Liu et al., 2006) . Recent data indicate NAPE-PLD localization already in neonatal mouse brain, with non-detectable enzyme levels during earlier developmental periods. This finding supports a role for 2-AG as primary eCB during neurodevelopment; however, possible mechanisms of activity-dependent AEA release, and receptor-level regulatory interactions between AEA and 2-AG signaling remain to be established.
Monoacylglycerol lipases 1/2 (MGLs) (Dinh et al., 2002; Muccioli et al., 2007) and fatty-acid amide hydrolases 1/2 (FAAH1/2) (Cravatt et al., 1996; Wei et al., 2006 ) have been established as major catabolic enzymes degrading 2-AG and AEA, respectively. Notably, however, the substrate-specificity and catabolic activity of FAAH may exhibit significant changes under specific conditions thus affecting not only AEA but also 2-AG levels Maione et al., 2006) . Whereas the cellular distribution of MGL1/2 during brain development is as yet unknown, FAAH has been detected in radial glia during late gestation and throughout the neonatal period Harkany et al., 2007) . In neurons, however, FAAH expression may be either transient or permanent: hippocampal interneurons undergoing intralaminar migration only transiently express FAAH in vitro (Berghuis et al., 2005) or during the first postnatal week in vivo (Morozov et al., 2004) suggesting the differential involvement of AEA signaling to interneuron specification. In sum, these data show that eCB levels are dynamically regulated during brain development.
Precise expression patterns are available for the CB1R in the developing CNS. CB1Rs have been detected as early as day 11 of gestation in the murine CNS with peak mRNA levels in cortical pyramidal cells by embryonic days 14-15 (Mulder et al., 2008) . In contrast, CB1R expression in interneurons becomes only detectable during late gestation/birth with persistently high expression levels postnatally Harkany et al., 2007) . Accordingly, CB1R levels are undetectable in post-mitotic interneuron progenitors at their extracortical origins (ganglionic eminences) or during tangential migration . Similar CB1R mRNA expression patterns have been reported during human pre-and postnatal CNS development by in situ hybridization (Wang et al., 2003) . Pharmacological studies indicate the functionality of CB1Rs in embryonic neural tissues since WIN55212-2, a cannabinoid receptor agonist, significantly stimulated [ 35 S]GTPγS binding in both rodent and human brains (Mato et al., 2003; Wang et al., 2003) .
Is the CB1R the only cannabinoid-sensing receptor expressed in the developing brain? In vitro data suggest that both stem cell differentiation and glial specification are affected by pharmacological modulation of CB2Rs, and glial cells may simultaneously express both CB1Rs and CB2Rs Molina-Holgado et al., 2007) . However, neither the spatial nor the temporal embryonic expression of this receptor class is known.
Similarly, multiple orphan receptors, including GPR35, GPR55, and GPR119 may have expression loci in the mammalian CNS (Brown, 2007; Lauckner et al., 2008; Sawzdargo et al., 1999) and thus, could affect particular cellular processes during neurodevelopment. This notion is reinforced by the robust effects of GPR55 activation on extracellular signal-regulated kinase (Erk1/2) pathways (Oka et al., 2007) , on intracellular Ca 2+ transients (Abe et al., 2005; Lauckner et al., 2008) , and on the activity of small GTPases (RhoA, cdc42, and Rac) (Lauckner et al., 2008; Ryberg et al., 2007) . Considering that these signal transduction mechanisms are pivotal for neuronal specification, axonal growth, and growth cone steering decisions mediated by eCBs , a key developmental role for GPR55 can be postulated. It is also important to note that coincident eCB actions on multiple receptor systems (e.g., CB1R, GPR55, transient receptor vanilloid potential 1 (TRPV1), and others), and their differential coupling to second messenger cascades may further increase the complexity of developmental eCB signaling. Overall, neuroanatomical findings furnish the concept that the eCB system is expressed and positioned during CNS development such that its activity can optimally control fundamental developmental processes (Fig. 1). 
Differential signaling through CB1 cannabinoid receptors underscores neuronal specification
CB1Rs belong to the superfamily of 7 transmembrane domain-containing G protein-coupled receptors (GPCRs), and exhibit 44% overall homology to the CB2R (Munro et al., 1993) . Recent advances in receptor biology argue that receptor multimers function as key signaling units (Devi, 2000) , and accordingly, CB1Rs likely signal as homodimers (Wager-Miller et al., 2002) . Receptor dimerization is a critical molecular phenomenon during neurodevelopment, as the diversity of interacting receptors, such as those of neurotrophins and growth factors (Berghuis et al., 2005; Williams et al., 2003) , recruited to the CB1R can further diversify and refine developmental eCB actions. CB1Rs preferentially couple to Gi/o proteins. Post-translational modification (splice variants) (Ryberg et al., 2005) , specific ligands, receptor interactions , interacting proteins (Niehaus et al., 2007) , or preferential recruitment of particular downstream effectors (Galve-Roperh et al., 2006) however may shift CB1R signaling such that Gs (Gq/11) protein coupling occurs (Lauckner et al., 2005) . Irrespective of the particular Gβγ protein complex (Iyengar, 2005) , CB1Rs are critical for the regulation of the activity of, e.g., ion channels, neurotransmitter transporters, metabolic enzymes, and cytoskeletal integrity Derkinderen et al., 1996; Derkinderen et al., 2003; He et al., 2005; Rios et al., 2006; van der Stelt et al., 2005) .
The 'on-demand' recruitment of second messengers to the CB1R, e.g., the Src/Stat3 Jordan et al., 2005) , Erk1/2 Derkinderen et al., 2003; Galve-Roperh et al., 2000; Rueda et al., 2002) , and PI3K/Akt pathways (Molina-Holgado et al., 2002) , and the modulation of sphingolipid-derived signaling mediators and cell death pathways (Guzman, 2003) enhance the potential of the CB1R to dynamically regulate the spatial and temporal coordination of e.g., neural progenitor proliferation and fate decision, migration, and lineage specification Harkany et al., 2007) . In sum, cross-talk between the eCB and other signaling systems can influence neurodevelopment. The interaction of alternative eCB signaling pathways, many of them as yet only partially known, converging on the CB1R provides a unifying mechanistic perspective explaining diverse developmental actions of eCB on various neuron populations.
A c c e p t e d
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Endocannabinoids regulate neuronal commitment and cell migration
During brain development, the establishment of eCB signaling networks coincides with the expansion of neural progenies and their engagement in establishing neuronal diversity (Galve-Roperh et al., 2006) . Functional eCB signaling in neurogenic proliferative zones, represented by DAGL and CB1R/CB2R expression (Aguado et al., 2005; Molina-Holgado et al., 2007; Mulder et al., 2008) , suggests that eCBs could provide extracellular cues instructing the cellular program of neural progenitors such that they generate appropriate contingents of cell lineages required to build the developing brain. A fine-tuned balance between progenitor cell proliferation and programmed death guarantees the generation of adequate quantities of neural cells during brain development. It is evident that eCBs regulate neural progenitor commitment and survival Guzman et al., 2001; Guzman et al., 2002; Mulder et al., 2008) . Neural progenitors possess a functional eCB signaling loop: the capacity to synthesize eCBs, functional CB1Rs, and catabolic enzyme(s) (Aguado et al., 2005) . CB1R activation is sufficient for progenitor proliferation to occur : whilst these actions are lacking in cnr1 -/-cells, they become significantly increased in faah -/-ones. The eCB system also plays a role in regulating the primary fate decision point of neural progenitors by modulating whether neural precursors commit to generate neurons or glia. Consequently, CB1R activation on neural progenitors promotes their differentiation into glial cells . In contrast, both pharmacological treatments (Rueda et al., 2002) , and eCBs decrease neurogenesis, and inhibit the expression of selective markers of early and terminally-differentiated neurons in vitro. Alternatively, SR141716, a selective CB1R antagonist, increases neuronal differentiation of neural progenitors (Jin et al., 2004; Rueda et al., 2002) . Collectively, these studies suggest the existence of an eCB tone actively modulating neural progenitor differentiation through the CB1R receptor in the developing brain.
The eCB/phytocannabinoid-induced switch that commits neural progenitors to gliogenesis at the expense of neurogenesis clearly poses the question whether eCB effects also impinge on neuronal migration, and on the acquiring of cellular (neurochemical/morphological) identity during terminal neuronal differentiation. Recent evidence indicates that eCBs modulate, through cell type-specific receptor systems and downstream signaling mechanisms, the chemotaxis of various cell types, including glial cells (Walter et al., 2003) , neurons (Berghuis et al., 2005) , immune cells (Kurihara et al., 2006; McHugh et al., 2007; Miller et al., 2007) , smooth muscle cells (Rajesh et al., 2007) , cancer cells (Ghosh et al., 2006; Preet et al., 2007) and HEK293 cells (Song et al., 2000) . It is important to note that eCBs often interact with other signaling systems, including neurotrophins (Berghuis et al., 2005) , growth factors (Preet et al., 2007) , and inflammatory cytokines (Rajesh et al., 2007) to induce cell migration. With regards to brain development, experimental evidence indicates that both eCBs and CB1R agonists induce the migration of late-gestational GABAergic interneurons known to undergo long-distance migration to reach their final positions in the developing cerebrum (Berghuis et al., 2005) . The finding that eCBs simultaneously inhibit the morphogenesis of GABAergic interneurons outline a complex, yet physiologically ideal signaling mechanism whereby eCBs control neuronal maturity (axonal/dendritic complexity) such that it is most compatible with particular stages of cell differentiation. In vivo support for CB1R-mediated chemotaxis is provided by the fact that prenatal  9 -THC increases the density of cholecystokinin-expressing interneurons in the neonatal rat hippocampus (Berghuis et al., 2005) , a finding compatible with in vitro data on eCB-induced interneuron M a n u s c r i p t Tibor Harkany et al. Endocannabinoids in the developing brain Date of submission : February 19, 2008 7 mobility. Overall, these data suggest that eCBs are instructive signals for both neuronal and glial cell migration and thus contribute to generating neuronal diversity in particular brain regions.
CB1 cannabinoid receptors are targeted to developing axons
The subcellular domains where CB1Rs are momentarily accessible to their ligands define the physiological functions eCB signaling subserves whilst regulating neuronal differentiation. It has recently been demonstrated that domain-specific endocytosis, a key mechanism limiting the surface expression of a range of axonal proteins (Sampo et al., 2003; Wisco et al., 2003) , determines the cell-surface availability of CB1Rs in neurons (Leterrier et al., 2006; McDonald et al., 2007a) : CB1Rs on the somatodendritic surface are internalized more rapidly than those in the axonal plasma membrane leading to a net receptor accumulation in the axon. Studies in numerous cellular models (Leterrier et al., 2004; Leterrier et al., 2006; McDonald et al., 2007a) have indicated that CB1Rs undergo constitutive endocytosis and recycling, leading to a pronounced intracellular pool of receptors at steady state. Inhibition of CB1R endocytosis, using pharmacological blockade or overexpression of dominant-negative dynamin-1, dynamin-2, eps15, or rab5 mutants, reveals a robust change in the cell surface distribution of CB1Rs from the axon to a non-polarized state with pronounced somatodendritic plasma-membrane expression (Leterrier et al., 2006; McDonald et al., 2007a) . It is also likely that transcytotic delivery of CB1Rs to the axonal plasma membrane from the somatodendritic cell-surface contributes to the generation of CB1R cell-surface polarity and this may act as a salvage pathway for somatodendritc receptors. The precise mechanisms underlying preferential endocytosis of CB1Rs within the somatodendritic compartment of neurons are yet unclear. The selective recruitment of specific anchoring proteins with a capacity to bind CB1Rs in axons together with subcellular differences in receptor densities (Rimmerman et al., 2008) and in the molecular composition of the internalization machinery, and adaptor complexes (Niehaus et al., 2007; Seong et al., 2005) may underscore prolonged stabilization of CB1Rs within axonal plasma membranes. It is, however, of major importance to define whether CB1R availability in various subcellular compartments is regulated by ligand availability or by constitutive receptor activity and trafficking; when eCB availability does not limit the recruitment of G proteins and downstream signaling. The concept that constitutive CB1R activity contributes to eCB signaling was initially supported by several lines of studies: fluorescent CB1R chimeras display high levels of constitutive endocytosis, leading to a marked intracellular localization at steady state, in HEK293 cells (D'Antona et al., 2006; Ellis et al., 2006; Leterrier et al., 2006) , and exposure to CB1R antagonists enhances cell-surface CB1R expression (D'Antona et al., 2006; Leterrier et al., 2004; Leterrier et al., 2006; Rinaldi-Carmona et al., 1998) , thought to reflect inhibition of constitutive endocytosis. However, work from the Irving laboratory (Coutts et al., 2001; McDonald et al., 2007a; McDonald et al., 2007b) argues that CB1R antagonists do not up-regulate cell surface targeting of wild-type CB1Rs in axons of hippocampal neurons. A significant shortcoming of earlier studies is that data on eCB levels were lacking and thus, the ability of cells to maintain an 'eCB tone' by producing endogenous ligands themselves (Turu et al., 2007) or through the cell culture media (e.g., serum components) (Stoddart et al., 2007) has not been excluded. Therefore, the persistent availability of low eCB levels may, in virtually all cellular systems, control basal CB1R trafficking and cell-surface availability. Data from Turu and colleagues (Turu et al., constitutive receptor activity is derived from studies with CB1R chimeras whereby mutagenesis prevents agonistinduced endocytosis and constitutive receptor activation (Hsieh et al., 1999; Roche et al., 1999) . Overall, constitutive CB1R endocytosis in the somatodendritic compartment appears to be controlled by mechanisms likely involving different motifs/conformational states within the CB1R and distinct from those utilized upon agonist-induced internalization. Considering that structural and conformational requirements of constitutive and agonist-induced receptor trafficking are distinct in many other GPCRs (Waldhoer et al., 2003; Whistler et al., 2002) , identifying particular structural domains of the CB1R that determine subcellular receptor targeting will be pivotal for our better understanding of CB1R signaling not only during neurodevelopment but also in many disease conditions in the postnatal brain. Selective axonal targeting of CB1Rs from the early period of acquiring neuronal polarity throughout neuronal specification suggests that this conserved mechanism is of key importance with regards to neuronal differentiation and synapse development.
Endocannabinoids shape neuronal connectivity
The survival of neurochemically-defined sets of neurons requires the correct patterning of axons and the establishment of functional synapses. Accordingly, the concept has recently evolved that eCB signaling through CB1Rs controls the initial phase of neurochemical specification and exerts differential effects on growth cone navigation, axonal elongation, and synaptogenesis of inhibitory interneurons and excitatory (pyramidal) cells in the mammalian cerebrum (Berghuis et al., 2004; Berghuis et al., 2005; Berghuis et al., 2007; Mulder et al., 2008) . This hypothesis is supported by recent data in chick and zebrafish models showing that CB1R expression follows neuronal differentiation from the earliest embryonic stages, and interfering with CB1R functions causes profound problems in axonal pathfinding and fasciculation (Watson et al., 2008) .
The concept that 'on-demand' eCB signaling links axonal specification in the early embryonic brain to synaptogenesis and synaptic plasticity during the neonatal period is supported by recent evidence identifying eCBs as a class of axon guidance cues as shown in chemotropic and galvanotropic growth cone turning assays in vitro . A unique feature of CB1R distribution in the fetal mouse and human brains is its association with several developing axonal trajectories in the white matter. This type of CB1R localization, widely considered as 'atypical' receptor positioning (Romero et al., 1997) , has recently been identified as a prerequisite of guiding the elongating axons to their targets (Mulder et al., 2008; Watson et al., 2008) , and to achieving proper synapse positioning of postsynaptic target cells . The evolving concept of eCB-driven synapse specification is further supported by the removal of CB1R from developing axonal tracts coincident with the conclusion of synaptogenesis and the selection of post-synaptic targets (Berghuis et al., 2005; Berghuis et al., 2007; Fernandez-Ruiz et al., 2000) , and the selective accumulation of CB1Rs in growth cones acquiring structural features of synapses, in particular their capacity of vesicular neurotransmitters release . Additional data show translocation of DAGL expression loci (Bisogno et al., 2003; Mulder et al., 2008) during local navigation and postsynaptic target selection of both local inhibitory afferents and corticothalamic and intercallosal pyramidal cell axons during corticogenesis: intrinsic DAGL/β activity within axonal growth cones is sustained throughout axonal navigation, with rapid down-regulation of DAGL/β levels upon postsynaptic target selection and synapse maturation. These changes in the sites of DAGL expression suggest that the specification and extension of axons towards postsynaptic target areas may require autocrine eCB signaling (Bisogno et al., 2003; Williams et al., 2003) , while the precise positioning of synapses on postsynaptic targets, the establishment of cell-to-cell contacts, and the onset of synaptic communication within target regions are controlled by the spatially compartmentalized actions of target-derived eCBs Harkany et al., 2007) . Overall, these data support that eCB signaling in the embryonic brain directly translates into retrograde synaptic signaling once synapse establishment concludes.
Conclusions
Multiple levels of evidence from complementary disciplines of developmental biology, molecular genetics, electrophysiology, neuropharmacology and the neurosciences demonstrate that eCB signaling modulates CNS patterning by tuning the size of neural progenitors pools generating neurons and glia, by defining the sizes of neuronal contingents undergoing radial or tangential migration to populate the developing cerebrum, and by controlling the morphological and functional specification of developing neurons (Fig. 1) . Therefore, eCB signaling networks are sufficiently organized to evolve into feedback loops underlying retrograde synaptic transmission when immature neuronal networks become operational. Epidemiological and genetic evidence show that interference with eCB signaling in the developing brain by, e.g., cannabis exposure (Huizink et al., 2006) , and genetic (cnr1, faah) variations (Ujike et al., 2002; Weiser et al., 2005) , have enduring impact on the establishment of cortical neuronal networks. The diversity of enzymes and receptors contributing to the onset of eCB signaling during brain development clearly requires the continued identification of molecular substrates of eCB synthesis, and degradation, together with defining the cellular context-specific recruitment of second messenger cascades to understand microenvironmental requirements necessary for physiological eCB signaling to occur during brain development. Understanding the temporal and spatial control of specific gene activation patterns regulated by prenatal drug exposure will lead to the characterization of novel, cannabis-sensitive cellular mechanisms controlling particular stages of neuronal development, and will ultimately reveal the neural basis of developmental defects imposed by prenatal cannabis abuse. 
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